AmadeusValue’s Newsletter
Subscribe
Sign in
Home
Chat
Archive
About
Part 2 / 2: Portfolio going into 2025
$BFF.IM, $SES.IM, $8291.JP, $CCG.AX - and more to come...
Jan 3
•
AmadeusValue
17
Share this post
AmadeusValue’s Newsletter
Part 2 / 2: Portfolio going into 2025
Copy link
Facebook
Email
Notes
More
4
Part 1 / 2: Update and context, approach going forward
Portfolio going into 2025 revealed in my next post
Jan 2
•
AmadeusValue
14
Share this post
AmadeusValue’s Newsletter
Part 1 / 2: Update and context, approach going forward
Copy link
Facebook
Email
Notes
More
Aclaris Therapeutics ($ACRS)
An intriguing busted biotech situation ($1.15 share price, $81.53m market cap, >$1.5m USD ADTV). Upside estimate of +27-58%, or assuming a six-month…
Feb 6, 2024
•
AmadeusValue
6
Share this post
AmadeusValue’s Newsletter
Aclaris Therapeutics ($ACRS)
Copy link
Facebook
Email
Notes
More
16
Comms Group (CCG AX)
An Australian nano-cap lollapalooza offering +170% to +250% returns over the next three years
Feb 25, 2022
•
AmadeusValue
10
Share this post
AmadeusValue’s Newsletter
Comms Group (CCG AX)
Copy link
Facebook
Email
Notes
More
7
My background, objectives and investment process
Inaugural post
Jun 11, 2021
•
AmadeusValue
9
Share this post
AmadeusValue’s Newsletter
My background, objectives and investment process
Copy link
Facebook
Email
Notes
More
3
Global opportunistic value investing in inefficient markets
Welcome to AmadeusValue’s Newsletter by me, AmadeusValue.
Jun 10, 2021
•
AmadeusValue
2
Share this post
AmadeusValue’s Newsletter
Global opportunistic value investing in inefficient markets
Copy link
Facebook
Email
Notes
More
AmadeusValue’s Newsletter
Global opportunistic value investing in inefficient markets
Subscribe
AmadeusValue’s Newsletter
Subscribe
About
Archive
Sitemap
Share this publication
amadeusvalue.substack.com
AmadeusValue’s Newsletter
Copy link
Facebook
Email
Notes
More
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts